Presented by your firm here

Made 18 Oct 2026 · scored in public

Forecasts

Nine dated, falsifiable calls. The percentage is our probability the call comes true by its deadline. Not investment advice.

Theses & forecasts

9 open0 right0 wrong– Brier score

Us vs the market

WETWIRED probabilityprediction marketF1 Neuralink: 30+ people implantedKalshi 74%65%F2 First human Blindsight implantby 30 Jun 202735%F3 Tesla + SpaceX merger announcedPolymarket 27%25%F4 Neuralink joins the Musk public stackby 31 Dec 202720%F5 Neuralink valued at $60B+ (secondary)Polymarket 57%50%F6 Eyes first: PRIMA gets FDA approvalby 31 Dec 202755%F7 Synchron starts its pivotal trialby 31 Dec 202750%F8 Neuracle IPO in Shanghaiby 31 Dec 202745%F9 Paradromics implants patient #2by 30 Jun 202775%WETWIRED probabilityprediction marketF1 Neuralink: 30+ people implantedKalshi 74%65%F2 First human Blindsight implantby 30 Jun 202735%F3 Tesla + SpaceX merger announcedPolymarket 27%25%F4 Neuralink joins the Musk public stackby 31 Dec 202720%F5 Neuralink valued at $60B+ (secondary)Polymarket 57%50%F6 Eyes first: PRIMA gets FDA approvalby 31 Dec 202755%F7 Synchron starts its pivotal trialby 31 Dec 202750%F8 Neuracle IPO in Shanghaiby 31 Dec 202745%F9 Paradromics implants patient #2by 30 Jun 202775%
Our probability that each call comes true by its deadline (bar), against the prediction-market price where one exists (diamond). Market prices read 18 Oct 2026; the right-hand note shows the market or the deadline. Sources: Kalshi, read 19 Oct 2026 Polymarket, read 19 Oct 2026 Polymarket, read 19 Oct 2026

Catalyst calendar

Dated events that move these calls, and the day each call resolves.

  1. Oct282026
  2. Dec62026
    by
  3. Dec312026
    by
    • Neuralink publishes a new patient count (Kalshi resolves on it) Implants (the platforms) Kalshi, read 18 Oct 2026
    • Neuralink's automated-surgery promise falls due Surgical robotics & delivery Reuters, 1 Jan 2026
    • F1 resolves: Neuralink: 30+ people implanted 65%
    • F3 resolves: Tesla + SpaceX merger announced 25%
    • F5 resolves: Neuralink valued at $60B+ (secondary) 50%
  4. Jun302027
    by
    • F2 resolves: First human Blindsight implant 35%
    • F9 resolves: Paradromics implants patient #2 75%
  5. Dec312027
    by
    • F4 resolves: Neuralink joins the Musk public stack 20%
    • F6 resolves: Eyes first: PRIMA gets FDA approval 55%
    • F7 resolves: Synchron starts its pivotal trial 50%
    • F8 resolves: Neuracle IPO in Shanghai 45%
Undated and rolling catalysts

The calls

F1by 65%
65%Kalshi 74%

Thesis: Neuralink's scale-up is real but slower than its price.

Neuralink reaches at least 30 people implanted (cumulative), confirmed by Neuralink or a major outlet, by 31 Dec 2026.

Why, market & sources
Catalyst
Neuralink count update; Kalshi resolves 31 Dec 2026
Why
12 people by Sep 2025, 21 by Jan 2026: about 2 a month. That pace lands in the high 30s by year end, and Musk promised "high-volume production" in 2026. We sit under the market because Neuralink has not published a total since January, and this call needs a public number. 50+ by year end: 15%, a sell against the market.
Investor read
A miss would weigh on secondary prices (see F5).
Market
Kalshi 74% (30+), 30% (40+), 19% (50+) Kalshi, read 18 Oct 2026
Sci-fi says
Neuromancer (1984): "jacking in" is a street-level habit. Reality: a few dozen trial participants, every one a medical case. Decades away.

Reuters, 9 Sep 2025 Neuralink, 27 Jan 2026 Reuters, 1 Jan 2026 Kalshi, read 18 Oct 2026

open made

F2by 35%
35%no market

Thesis: Vision is Neuralink's next product, and it is late.

Neuralink publicly confirms its first human Blindsight (vision) implant by 30 Jun 2027.

Why, market & sources
Catalyst
First Blindsight implant announcement
Why
Musk has named three windows and missed them: "later this year" (Mar 2025), "early 2026" in the UAE (May 2025), "6 to 12 months" (Jun 2025). As of 18 Oct 2026 the count of human Blindsight implants is 0. A 1M-view recycled clip this week shows hype is ahead of the data. The FDA Breakthrough designation helps the paperwork, not the surgery date.
Investor read
A first implant would mean a second product line. Until then, read Musk's dates as marketing.
Market
No prediction market found.
Sci-fi says
Geordi La Forge's VISOR (Star Trek: TNG, 1987). Reality: a first implant would give low-resolution flashes of light, nowhere near VISOR sight.

MobiHealthNews, Mar 2025 Teslarati, May 2025 Neuralink trials page Community Note on the viral clip, 16 Oct 2026

open made

F3by 25%
25%Polymarket 27%

Thesis: A Musk mega-merger is likely, but more likely in 2027. speculation

A Tesla–SpaceX merger or takeover is officially announced by 31 Dec 2026.

Why, market & sources
Catalyst
Tesla AGM, due by 6 Dec 2026
Why
Barclays (14 Oct) calls a tie-up "increasingly the consensus expectation" and points to Tesla's AGM, due by 6 Dec, as the vote. Musk talks of "more and more overlap", and the two already share the Terafab chip plant. But Barclays also says a late-October or November announcement makes AGM approval harder. Our view: likely in 2027, less likely in 2026.
Investor read
Puts Optimus, Grok and Terafab under one public roof. Still no Neuralink.
Market
Polymarket 29% (by 31 Dec 2026), 64% (by end-2027) Polymarket, read 18 Oct 2026
Sci-fi says
Weyland-Yutani (Alien): one conglomerate building ships, robots and synthetic minds. Reality: the corporate structure is closer than the androids.

Yahoo Finance, 16 Oct 2026 (Barclays note) Polymarket, read 18 Oct 2026 Wikipedia: SpaceX (IPO, Terafab)

open made

F4by 20%
20%no market

Thesis: Neuralink is the missing piece of the Musk stack. speculation

By 31 Dec 2027, Neuralink is announced as merging into SpaceX or Tesla, or files for its own IPO.

Why, market & sources
Catalyst
Any merger filing or IPO filing
Why
The precedent exists: xAI was folded into SpaceX in Feb 2026 at a reported $250B, months before SpaceX listed. Neuralink's secondary price has gone from a $9B round (Jun 2025) to about $42B (Jul 2026). Against it: no approved product, no revenue, and FDA trials make it an awkward thing for a public parent to own. This is speculation, priced as such.
Investor read
The only realistic route for public investors into Neuralink.
Market
No prediction market found.
Sci-fi says
The Culture's neural lace (Iain M. Banks). Musk took the word from Banks. In the novels the lace is standard kit in an AI-run civilisation. An AI + robots + BCI Musk stack is the nearest real analogue. Still fiction.

Wikipedia: SpaceXAI (xAI deal, Feb 2026) Neuralink, Series E, Jun 2025 Business Insider, Jul 2026

open made

F5by 50%
50%Polymarket 57%

Thesis: Secondary prices are momentum, not fundamentals.

Neuralink's Nasdaq Private Market implied valuation reaches $60B or more on any day by 31 Dec 2026.

Why, market & sources
Catalyst
Daily Nasdaq Private Market price
Why
Secondary prices have run far ahead of patient numbers: about $42B in July, and a $257.66 NPM share price on 2 Oct. Merger talk lifts every Musk private name. But no new primary round has been confirmed since the Series E. A coin flip, slightly under the market.
Investor read
Buying at $60B+ prices in approval, scale and a merger at once.
Market
Polymarket 55% ($60B); the $50B line has already resolved yes Polymarket, read 18 Oct 2026
Sci-fi says
Altered Carbon: the cortical stack is the most valuable object in society. Markets are pricing the stack. The approved device count is still 0.

Business Insider, Jul 2026 Nasdaq Private Market, 2 Oct 2026 Polymarket, read 18 Oct 2026

open made

F6by 55%
55%no market

Thesis: Eyes before brains: the first US BCI revenue is retinal.

Science Corp.'s PRIMA retinal implant gets US FDA marketing approval (PMA, HDE or De Novo) by 31 Dec 2027, before any brain-implanted BCI.

Why, market & sources
Catalyst
FDA decision on PRIMA (no date published)
Why
PRIMA is already CE-marked and on sale in Europe (Jul 2026), holds FDA Breakthrough and Humanitarian Use designations, and has 36-month data on 38 trial patients. Every brain-implanted BCI in the US is still in feasibility or pre-pivotal studies. Risk: FDA timing.
Investor read
First reimbursable US BCI revenue. Private only (Science Corp.).
Market
No prediction market found.
Sci-fi says
Steve Austin's bionic eye (The Six Million Dollar Man, 1974). Reality: a 378-pixel chip that lets patients read letters. No 20x zoom yet.

Science Corp., 5 Oct 2026 Science Corp., 13 Oct 2026 TIME Best Inventions 2026

open made

F7by 50%
50%no market

Thesis: Synchron is the US brain-BCI closest to an approval path.

Synchron announces the first implant in a pivotal (approval) trial by 31 Dec 2027.

Why, market & sources
Catalyst
Pivotal-trial start
Why
COMMAND met its primary safety endpoint (Sep 2024), and the $200M Series D (Nov 2025) was raised to move toward approval. A report says the CEO plans to file for a pivotal trial, and a $275M Series E has been reported, but neither is confirmed unverified. No public start date.
Investor read
Likely trigger for its next priced round or IPO talk.
Market
No prediction market found.
Sci-fi says
Iron Man's Jarvis: run your devices by thought. Reality: patients click and type by thought. No conversation, no suit.

Synchron / Business Wire, Sep 2024 Business Wire, Nov 2025 neurotech.com, 9 Jun 2026 (unverified) Dealroom, Aug 2026

open made

F8by 45%
45%no market

Thesis: China will list the first approved implanted-BCI pure play.

Neuracle (Boraycon) prices an IPO on Shanghai's STAR Market by 31 Dec 2027, the first listing of an approved implanted-BCI maker.

Why, market & sources
Catalyst
STAR Market filing accepted
Why
China gave the world's first market approval for an implanted BCI (13 Mar 2026) and an insurance code within 48 hours. Neuracle finished IPO counselling on 6 May 2026. Policy wind is strong. Against: STAR listing queues and little product revenue so far (36Kr).
Investor read
Gives the sector its first public comparable.
Market
No prediction market found.
Sci-fi says
Ghost in the Shell: a state that industrialises the cyberbrain. Reality: one approved device for paralysis, but the state-backed scale-up is already visible.

Paradromics analysis, 30 Apr 2026 Bird & Bird, 2026 36Kr, 11 Jun 2026 SCMP, Sep 2026

open made

F9by 75%
75%no market

Thesis: Speech is the killer app, and Paradromics is a leader.

Paradromics announces a second chronic Connect-One participant by 30 Jun 2027.

Why, market & sources
Catalyst
Second Connect-One implant
Why
The FDA approved the study (Nov 2025) at three sites. Patient #1 (Jun 2026) is speaking in real time (Sep 2026), and in Aug 2026 the FDA cleared use with personal phones and laptops. The main risk is a recruitment or safety pause.
Investor read
De-risks the speech thesis ahead of its next raise.
Market
No prediction market found.
Sci-fi says
Star Trek's universal translator: thought into spoken words. Reality: one woman in Michigan answering open questions in real time.

Paradromics, 17 Jun 2026 Business Wire, 14 Sep 2026 Business Wire, 26 Aug 2026

open made

Scorecard

Every call, its deadline and how it resolved. Market prices read 18 Oct 2026. Brier score appears once calls resolve (lower is better; 0.25 = coin flip).

#CallDeadlineOur %MarketResult
F1Neuralink: 30+ people implanted31 Dec 202665%Kalshi 74%open
F2First human Blindsight implant30 Jun 202735%–open
F3Tesla + SpaceX merger announced31 Dec 202625%Polymarket 29%open
F4Neuralink joins the Musk public stack31 Dec 202720%–open
F5Neuralink valued at $60B+ (secondary)31 Dec 202650%Polymarket 55%open
F6Eyes first: PRIMA gets FDA approval31 Dec 202755%–open
F7Synchron starts its pivotal trial31 Dec 202750%–open
F8Neuracle IPO in Shanghai31 Dec 202745%–open
F9Paradromics implants patient #230 Jun 202775%–open
How we score

Dated, falsifiable calls. confidence = WETWIRED probability the call happens by the deadline. Calls are never edited after publishing; a changed view is a new call. On the deadline status becomes right, wrong or void, with resolved_on and resolution_source filled in. Brier score = mean of (p - outcome)^2 over resolved calls (outcome 1 or 0). Market prices are snapshots read on the made date.

The sci-fi lines on each call are framing, not evidence.